Duncker Streett & Co’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Duncker Streett & Co’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.7K	Hold	300	–	–	0.01%	364
2026 Q1	$26K	Hold	300	–	–	﹤0.01%	373
2025 Q4	$25.4K	Hold	300	–	–	﹤0.01%	375
2025 Q3	$21.8K	Hold	300	–	–	﹤0.01%	386
2025 Q2	$19.7K	Hold	300	–	–	﹤0.01%	390
2025 Q1	$21.2K	Hold	300	–	–	﹤0.01%	377
2024 Q4	$19.7K	Hold	300	–	–	﹤0.01%	396
2024 Q3	$21.2K	Hold	300	–	–	﹤0.01%	377
2024 Q2	$19.9K	Hold	300	–	–	﹤0.01%	377
2024 Q1	$20.4K	Hold	300	–	–	﹤0.01%	370
2023 Q4	$18.5K	Hold	300	–	–	﹤0.01%	372
2023 Q3	$17.7K	Hold	300	–	–	﹤0.01%	372
2023 Q2	$17.9K	Hold	300	–	–	﹤0.01%	371
2023 Q1	$17.5K	Hold	300	–	–	﹤0.01%	366
2022 Q4	$18.6K	Hold	300	–	–	﹤0.01%	376
2022 Q3	$17K	Hold	300	–	–	﹤0.01%	366
2022 Q2	$19K	Hold	300	–	–	﹤0.01%	369
2022 Q1	$19K	Hold	300	–	–	﹤0.01%	382
2021 Q4	$20K	Hold	300	–	–	﹤0.01%	413
2021 Q3	$18K	Hold	300	–	–	﹤0.01%	411
2021 Q2	$19K	Hold	300	–	–	﹤0.01%	413
2021 Q1	$18K	Hold	300	–	–	﹤0.01%	409
2020 Q4	$18K	Hold	300	–	–	﹤0.01%	416
2020 Q3	$16K	Hold	300	–	–	﹤0.01%	402
2020 Q2	$15K	Hold	300	–	–	﹤0.01%	413
2020 Q1	$13K	Hold	300	–	–	﹤0.01%	419
2019 Q4	$16K	Buy	+300	New	+$14.8K	﹤0.01%	441
2019 Q3	–	Sell	-300	Closed	-$15K	–	360
2019 Q2	$15K	Hold	300	–	–	﹤0.01%	462
2019 Q1	$15K	Hold	300	–	–	﹤0.01%	472
2018 Q4	$14K	Hold	300	–	–	﹤0.01%	469
2018 Q3	$17K	Hold	300	–	–	﹤0.01%	473
2018 Q2	$15K	Hold	300	–	–	﹤0.01%	484
2018 Q1	$15K	Hold	300	–	–	﹤0.01%	482
2017 Q4	$15K	Hold	300	–	–	﹤0.01%	483
2017 Q3	$16K	Hold	300	–	–	﹤0.01%	475
2017 Q2	$16K	Hold	300	–	–	0.01%	481
2017 Q1	$15K	Hold	300	–	–	﹤0.01%	500
2016 Q4	$14K	Hold	300	–	–	﹤0.01%	506
2016 Q3	$15K	Hold	300	–	–	0.01%	478
2016 Q2	$14K	Hold	300	–	–	0.01%	485
2016 Q1	$14K	Hold	300	–	–	0.01%	486
2015 Q4	$16K	Hold	300	–	–	0.01%	472
2015 Q3	$15K	Hold	300	–	–	0.01%	477
2015 Q2	$17K	Sell	300 -600	-67%	-$35.1K	0.01%	479
2015 Q1	$52K	Hold	900	–	–	0.02%	378
2014 Q4	$45K	Hold	900	–	–	0.01%	389
2014 Q3	$42K	Hold	900	–	–	0.01%	395
2014 Q2	$41K	Hold	900	–	–	0.01%	408
2014 Q1	$38K	Hold	900	–	–	0.01%	402
2013 Q4	$35K	Hold	900	–	–	0.01%	396
2013 Q3	$32K	Hold	900	–	–	0.01%	386
2013 Q2	$30K	Buy	+900	New	+$29.9K	0.01%	393

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Duncker Streett & Co's IHE Position: Q2 2026 in Review

Duncker Streett & Co held its iShares US Pharmaceuticals ETF (IHE) position steady in Q2 2026 at 300 shares worth $29.7K. The position accounts for 0.01% of the portfolio, ranked #364.

Duncker Streett & Co first reported a position in IHE in Q2 2013 and has held it in 52 quarters since. The position peaked at $52K in Q1 2015. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Duncker Streett & Co held 300 shares of iShares US Pharmaceuticals ETF worth $29.7K as of Q2 2026.
Duncker Streett & Co left its iShares US Pharmaceuticals ETF share count unchanged in Q2 2026.
iShares US Pharmaceuticals ETF made up 0.01% of Duncker Streett & Co's portfolio in Q2 2026, its #364 holding.
Duncker Streett & Co first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 52 quarters since.
Duncker Streett & Co's iShares US Pharmaceuticals ETF position peaked at $52K in Q1 2015.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Duncker Streett & Co's 13F filing for Q2 2026, filed 28 Jul 2026.